Advertisement

Topics

AbbVie Announces Positive Pivotal Phase 3 Data Demonstrating Investigational Medicine Elagolix ...

09:00 EDT 19 Oct 2016 | BioMedReports - Blog

In the two studies, both doses of Elagolix administered orally demonstrated a statistically significant (p ≤ 0.001) improvement versus placebo in the percentage of DYS

Read more...

Original Article: AbbVie Announces Positive Pivotal Phase 3 Data Demonstrating Investigational Medicine Elagolix ...

NEXT ARTICLE

More From BioPortfolio on "AbbVie Announces Positive Pivotal Phase 3 Data Demonstrating Investigational Medicine Elagolix ..."

Quick Search
Advertisement